WO1995019183A1 - Expression de cd44 dans les cellules des muscles lisses - Google Patents

Expression de cd44 dans les cellules des muscles lisses Download PDF

Info

Publication number
WO1995019183A1
WO1995019183A1 PCT/US1995/000740 US9500740W WO9519183A1 WO 1995019183 A1 WO1995019183 A1 WO 1995019183A1 US 9500740 W US9500740 W US 9500740W WO 9519183 A1 WO9519183 A1 WO 9519183A1
Authority
WO
WIPO (PCT)
Prior art keywords
smooth muscle
muscle cell
compound
expression
cells
Prior art date
Application number
PCT/US1995/000740
Other languages
English (en)
Inventor
Qi He
Edgar Haber
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Priority to JP7519223A priority Critical patent/JPH09508265A/ja
Priority to AU18326/95A priority patent/AU689226B2/en
Priority to EP95910105A priority patent/EP0806965A4/fr
Publication of WO1995019183A1 publication Critical patent/WO1995019183A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention se rapporte à des procédés de traitement de l'artériosclérose ou de la resténose vasculaire qui consistent à inhiber la migration ou la prolifération des cellules des muscles lisses induite par CD44, ainsi qu'à des procédés de criblage afin d'identifier des composés capables d'inhiber l'expression de CD44, d'inhiber la migration des cellules des muscles lisses induite par CD44, et d'inhiber la prolifération des cellules des muscles lisses induite par CD44.
PCT/US1995/000740 1994-01-18 1995-01-18 Expression de cd44 dans les cellules des muscles lisses WO1995019183A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7519223A JPH09508265A (ja) 1994-01-18 1995-01-18 平滑筋細胞におけるｃｄ４４発現
AU18326/95A AU689226B2 (en) 1994-01-18 1995-01-18 CD44 expression in smooth muscle cells
EP95910105A EP0806965A4 (fr) 1994-01-18 1995-01-18 Expression de cd44 dans les cellules des muscles lisses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18315694A 1994-01-18 1994-01-18
US08/183,156 1994-01-18

Publications (1)

Publication Number Publication Date
WO1995019183A1 true WO1995019183A1 (fr) 1995-07-20

Family

ID=22671682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/000740 WO1995019183A1 (fr) 1994-01-18 1995-01-18 Expression de cd44 dans les cellules des muscles lisses

Country Status (5)

Country Link
EP (1) EP0806965A4 (fr)
JP (1) JPH09508265A (fr)
AU (1) AU689226B2 (fr)
CA (1) CA2179391A1 (fr)
WO (1) WO1995019183A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0846001A1 (fr) * 1995-08-14 1998-06-10 Icn Pharmaceuticals Regulation de l'expression du gene codant pour cd44, a des fins therapeutiques
US5942417A (en) * 1996-07-15 1999-08-24 Human Genome Sciences, Inc. CD44-like protein and nucleic acids
CN112673983A (zh) * 2020-12-21 2021-04-20 重庆工商大学 一种基于糖基化改性大豆分离蛋白的宠物咬胶的制备方法及产品

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648517B (zh) * 2011-03-24 2016-04-20 纽瑞姆制药（1991）有限公司 神经保护肽

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007505A1 (fr) * 1991-07-03 1994-04-14 Norpharmco Inc. Utilisation de l'acide hyaluronique sous differentes formes contre la recidive de la stenose arterielle

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANTI-CANCER DRUG DESIGN, Volume 6, issued December 1991, MIRABELLI et al., "In Vitro and in Vivo Pharmacologic Activities of Antisense Oligonucleotides", pages 647-661. *
CELL, Volume 61, issued 29 June 1990, ARUFFO et al., "CD44 is the Principal Cell Surface Receptor For Hyaluronate", pages 1303-1313. *
CELL, Volume 65, issued 05 April 1991, GUNTHERT et al., "A New Variant of Glycoprotein CD44 Confers Metastatic Potential to Rat Carcinoma Cells", pages 13-24. *
JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 267, No.7, issued 05 March 1992, JACKSON et al., "Multiple Variants of the Human Lymphocyte Homing Receptor CD44 Generated by Insertions at a Single Site in the Extracellular Domain", pages 4732-4739. *
JOURNAL OF CELL BIOLOGY, issued December 1992, Volume 119, No. 6, HE et al., "Molecular Isoforms of Murine CD44 and Evidence That the Membrane Proximal Domain is Not Critical for Hyaluronate Recognition", pages 1711-1719. *
SCIENCE, Volume 257, issued 31 July 1992, ARCH et al., "Participation in Normal Immune Responses of a Metastasis-Inducing Splice Variant of CD44", pages 682-685. *
See also references of EP0806965A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0846001A1 (fr) * 1995-08-14 1998-06-10 Icn Pharmaceuticals Regulation de l'expression du gene codant pour cd44, a des fins therapeutiques
EP0846001A4 (fr) * 1995-08-14 1999-10-20 Icn Pharmaceuticals Regulation de l'expression du gene codant pour cd44, a des fins therapeutiques
US5942417A (en) * 1996-07-15 1999-08-24 Human Genome Sciences, Inc. CD44-like protein and nucleic acids
CN112673983A (zh) * 2020-12-21 2021-04-20 重庆工商大学 一种基于糖基化改性大豆分离蛋白的宠物咬胶的制备方法及产品

Also Published As

Publication number Publication date
EP0806965A4 (fr) 2000-06-07
EP0806965A1 (fr) 1997-11-19
CA2179391A1 (fr) 1995-07-20
JPH09508265A (ja) 1997-08-26
AU1832695A (en) 1995-08-01
AU689226B2 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
Cherayil et al. Molecular cloning of a human macrophage lectin specific for galactose.
Wilting et al. The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues
Tedesco et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
Burger et al. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells
Watt et al. PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells
Small et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.
Salles et al. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies
Sers et al. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread
JP5650038B2 (ja) インテグリンヘテロ二量体およびそのサブユニット
JPH07501212A (ja) ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
EP0362278A1 (fr) Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer
US20090012020A1 (en) Inhibiting formation of atherosclerotic lesions
Jones et al. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis
Arencibia et al. Collagen receptor on T lymphocytes and the control of lymphocyte motility
HU215778B (hu) Eljárás szindekántartalom kimutatására biológiai anyagokban, így szövetekben és testnedvekben, a sejtek rosszindulatú transzformációinak jelzésére
US20040072259A1 (en) Methods and products for manipulating hematopoietic stem cells
AU689226B2 (en) CD44 expression in smooth muscle cells
US6358915B1 (en) Methods for inhibiting metastasis
Ruegg et al. B4B, a novel growth-arrest gene, is expressed by a subset of progenitor/pre-B lymphocytes negative for cytoplasmic mu-chain.
US7524622B2 (en) Methods for increasing production of IFN-gamma in natural killer cells expressing LLT1 receptor
Chakrabarti et al. Control of islet intercellular adhesion molecule-1 expression by interferon-α and hypoxia
Rosewicz et al. Antiproliferative effects of interferon alpha on human pancreatic carcinoma cell lines are associated with differential regulation of protein kinase C isoenzymes.
Navarrete Santos et al. Regulation by transforming growth factor-beta1 of class II mRNA and protein expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis.
EP1220919A2 (fr) C4.4a, antigene associee a la metastase
US20080057579A1 (en) Methods and products for manipulating hematopoietic stem cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2179391

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995910105

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995910105

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995910105

Country of ref document: EP